CN114958780B - 一种牛Aichivirus D病毒分离株及其应用 - Google Patents
一种牛Aichivirus D病毒分离株及其应用 Download PDFInfo
- Publication number
- CN114958780B CN114958780B CN202210630701.8A CN202210630701A CN114958780B CN 114958780 B CN114958780 B CN 114958780B CN 202210630701 A CN202210630701 A CN 202210630701A CN 114958780 B CN114958780 B CN 114958780B
- Authority
- CN
- China
- Prior art keywords
- virus
- aichivirus
- bovine
- vaccine
- yak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000861568 Aichivirus D Species 0.000 title claims abstract description 47
- 241000283690 Bos taurus Species 0.000 title claims abstract description 33
- -1 pplication Species 0.000 title description 3
- 229960005486 vaccine Drugs 0.000 claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 40
- 238000011161 development Methods 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 210000003501 vero cell Anatomy 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 241001036151 Aichi virus 1 Species 0.000 description 6
- 241000711443 Bovine coronavirus Species 0.000 description 6
- 241000702673 Bovine rotavirus Species 0.000 description 6
- 241000709691 Enterovirus E Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 244000309466 calf Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 241001468000 Aichivirus B Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241001468006 Kobuvirus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940060184 oil ingredients Drugs 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001247911 Aichivirus A Species 0.000 description 1
- 241000986789 Aichivirus C Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001379910 Ephemera danica Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241001416503 Sciurus carolinensis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 241000228829 unclassified Kobuvirus Species 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
本发明公开了一种牛Aichivirus D病毒分离株及其应用,属于生物技术和病毒学技术领域,该病毒分离株的分类命名为牦牛Aichivirus D病毒BKV/Yak/DF77/2021/CHN,保藏编号是:CCTCC NO:V202228。本发明所提供的毒株具有较高的毒价,将该病毒株制备成灭活疫苗后能产生较高的抗体,可以作为疫苗研制的候选毒株,在牛Aichivirus D病毒所致疾病的防治与诊断方面具有非常好的应用前景。
Description
技术领域
本发明涉及生物技术和病毒学领域,具体涉及一种牛Aichivirus D病毒分离株及其应用。
背景技术
库布(kobuvirus)病毒属于小RNA病毒科(Picornaviridae),病毒基因组由一个5'UTR,一个大的开放阅读框(ORF)和一个3'UTR区域组成。Kobuvirus病毒是腹泻的病原,其具有强大的遗传多样性、高重组频率和RNA复制取代率。目前,已知有6种kobuvirus(Aichivirus A-F)和3种未分类的kobuvirus(灰松鼠库布病毒、挪威大鼠库布病毒和蝙蝠库布病毒)。Aichivirus是小RNA病毒科的一个新属,从人和多种动物及其所在环境中发现该病毒的存在,是一种引起动物腹泻的新发病原。目前该病毒已在包括中国在内的世界十多个国家被检出,具有广泛的地域分布。
Aichivirus A-F中,其中Aichivirus A在猫、羊、鼠中有发现,Aichivirus B在牛、雪貂、绵羊中有发现,而Aichivirus C只在猪中有发现。而感染牛的爱知病毒目前有Aichivirus B(AiV-B)和Aichivirus D(AiV-D),AiV-B已在我国牛养殖集群区流行,而另外一种能感染牛的AiV-D,国内未见报道,Keha-moAbi等在2021年利用病毒宏基因组学方法在藏羊腹泻粪便中发现,并成功地利用RT-PCR从腹泻粪便中获得了完整的科布病毒基因组。全基因组序列长度为8485个核苷酸,符合标准的小RNA病毒基因组结构,分离得到的基因组与Aichivirus D1基因型1-22-KoV株和Aichivirus D2基因型2-44-KoV株的同源性分别为62.9%和77.8%,根据国际病毒分类委员会(ICTV)的物种分类标准,新发现的库布病毒属于Aichivirus D(Keha-mo Abi,et al.Identification of a novel Aichivirus D insheep.Infection,Genetics and Evolution 91(2021)104810.)。目前还未有从牛中成功分离Aichivirus D的报道。
因此,迫切需要从牛中分离出我国的流行毒株Aichivirus D,以研制疫苗来预防该病的发生,减少该病毒对养牛业造成的经济损失。
发明内容
本发明的目的是提供一种牛Aichivirus D病毒分离株及其应用,该Aichivirus D病毒分离株(即本文中所述的BKV/Yak/DF77/2021/CHN毒株)制备成疫苗免疫后能产生较高水平的抗体,能够广泛用于临床牛Aichivirus D病毒疫苗和相关疾病的鉴别诊断,填补了目前我国尚无自主研发的预防或治疗牛Aichivirus D病毒所致疾病产品制备技术的空白。
为了实现本发明目的,采用的技术方案如下:
第一方面,本发明提供一种牛Aichivirus D病毒分离株,其特征在于,该分离株的微生物保藏编号为CCTCC NO:V202228。
第二方面,本发明提供一种前述的牛Aichivirus D病毒分离株在制备用于预防和/或治疗牛Aichivirus D病毒所致疾病产品中的应用。
本发明术语“预防”指通过给予根据本发明的疫苗组合物抑制牛腹泻或推迟疾病发作的所有行为。
术语“治疗”指通过给予根据本发明的疫苗组合物使牛腹泻病毒感染引起的症状减轻或好转的所有行为。
进一步地,所述产品为疫苗或药物。
进一步地,所述疫苗选自灭活疫苗、弱毒疫苗、减毒活疫苗、基因工程疫苗、多肽疫苗中的一种或几种。
术语“疫苗”在本文中广义地定义为是指可施用形式的任何类型的生物物质,其能够在接种了该疫苗的动物中刺激免疫应答。疫苗一般而言可以基于病毒本身(例如灭活的/失活的或减毒的)。在本发明一个实施方案中,所述疫苗(免疫原性组合物)优选包括灭活的/失活形式的病毒物质、或者作为亚单位疫苗存在的病毒的抗原性部分。
第三方面,本发明提供一种前述的牛Aichivirus D病毒分离株制备的抗牛Aichivirus D病毒抗体。
第四方面,本发明提供一种含有前述的抗牛Aichivirus D病毒抗体的药物。
第五方面,本发明提供前述牛Aichivirus D病毒分离株或前述抗牛Aichivirus D病毒抗体在制备牛Aichivirus D病毒所致疾病的检测试剂中的应用。
第六方面,本发明提供一种疫苗组合物,包括有效量的前述的牛Aichivirus D病毒分离株。
本文所用术语“有效量”在针对组合物的背景下,意指免疫原性组合物弄够诱导免疫应答的量,所述免疫应答降低感染的发生率或者降低感染的严重性或减少动物中疾病的发生。具体而言,有效量是指每剂量的集落形成单位(CFU)。或者,在治疗的背景下,术语“有效量”是指足以实现以下目的的治疗的量:降低或缓解疾病或病症(或者一或多种其症状)的严重性或持续时间,防止疾病或病症的进展,引起疾病或病症的退化,防止与疾病或病症相关的一或多种症状的复发、发展、发作、或进行,或者增强或改善另一种治疗或治疗剂的预防或疗效。所用的成分和待施用的组合物的精确的量将根据因素如治疗的疾病的类型,待治疗的动物的类型和年龄,施用的方式,以及组合物中的其它成分而变化。
进一步地,所述疫苗组合物还包括药物或兽医学接受的载剂。
药物或兽医学接受的载剂”包括任何的或者所有的溶剂、分散介质、包被、佐剂、稳定剂、稀释剂、防腐剂、坑细菌和抗真菌剂、等渗剂、吸附延缓剂,等等。在一些优选的实施方案中,以及特别是包括冻干的免疫原性组合物的那些,用于本发明的稳定剂包括用于冻干或者冷冻干燥的稳定剂。
“稀释剂”可包括水、盐水、右旋糖、乙醇、甘油,等等。等渗剂可包括氯化钠、右旋糖、甘露醇、山梨醇、和乳糖,等等。稳定剂包括白蛋白和乙二胺四乙酸的碱性盐,等等。
在本发明的一些实施方案中,本发明的疫苗组合物还包括佐剂。所述佐剂包括油佐剂,其包括但不限于动物油、植物油或矿物油、白油、角鲨烷或角鲨烯、德雷克油(Drakeoil)。上述油佐剂既可以是来源,也可以是经过人工合成获得的。
本发明中,所述疫苗组合物包括但不限于水包油乳液、油包水乳液或双重乳液;所述双重乳液表现为水包油包水乳液。
第七方面,本发明提供前述疫苗组合物的制备方法,培养增殖牛Aichivirus D病毒分离株,灭活后制备成疫苗产品。
除非另有定义,本文所使用的所有的技术和科学术语具有本发明提交时所属领域内技术人员通常所理解的相同含义。术语的含义和范围应当是清楚的;然而,如果有任何潜在歧义的情况,本文提供的定义优先于任何字典的或外部的定义。在本文中,使用“或”意味着“和/或”除非另有陈述。另外,使用术语“包括”,以及其它形式如“包含”和“含有”并不是限制性的。
有益效果:
(1)本发明在腹泻牦牛粪便样本中检出牦牛Aichivirus D病毒并获得一个完整的基因组,首次证实牦牛Aichivirus D病毒在国内的存在,使牦牛Aichivirus D病毒的防控更具有针对性和有效性,在牦牛Aichivirus D病毒灭活疫苗、弱毒疫苗的应用研究方面具有重要的价值。
(2)本发明使用牦牛Aichivirus D病毒分离株制备用于预防牦牛Aichivirus D病毒所致腹泻的疫苗,将该疫苗免疫动物后,具有很好的安全性、免疫原性,在观察时间内,均无任何不良反应,能刺激机体产生高效价的特异性血清中和抗体。
附图说明
图1是本发明BKV/Yak/DF77/2021/CHN毒株致Vero细胞病变;其中,A:正常的Vero细胞;B:蚀斑纯化产生病变的Vero细胞;C:间接免疫荧光鉴定;D:透射电镜
图2是本发明分离株的PCR检测;其中,凝胶电泳加样顺序依次为:泳道1:阳性对照;泳道2:阴性对照;泳道3:BKV/Yak/DF77/2021/CHN;M:MarkerⅡ,由上到下依次为1200bp、900bp、700bp、500bp、300bp、100bp;
图3是本发明BKV/Yak/DF77/2021/CHN特异性、纯净性检测;其中,泳道1:AiV D阳性对照;泳道2:BKV/Yak/DF77/2021/CHN AiV D检测;泳道3:AiV D阴性对照;泳道4:BRV阳性对照;泳道5:BRV阴性对照;泳道6:BKV/Yak/DF77/2021/CHN BRV检测;泳道7:BcoV阳性对照;泳道8:BcoV阴性对照;泳道9:BKV/Yak/DF77/2021/CHN BcoV检测;泳道10:BEV阳性对照;泳道11:BEV阴性对照;泳道12:BKV/Yak/DF77/2021/CHN BEV检测;M:MarkⅡ,由上到下依次为1200bp、900bp、700bp、500bp、300bp、100bp;
图4是本发明分离株制备的灭活疫苗免疫犊牛后中和抗体水平的测定。
具体实施方式
以下将配合实施例来详细说明本发明的实施方式,藉此对本发明如何应用技术手段来解决技术问题并达成技术功效的实现过程能充分理解并据以实施。
本发明所应用的方法可以采用病毒研究领域中常用的方法,而不仅限于本发明实施例的具体记载。下述实施例中所用的实验方法如无特殊说明,均按照常规实验条件或按照制造厂商说明书建议的条件。下述实施例中所用的试剂、材料等,如无特殊说明,均可从商业途径获得。
实施例1牦牛AiV D病毒的分离鉴定
1.1牦牛AiV D病毒的分离
首先观察牛群发病情况,采集初步诊断为腹泻的的牛粪便样本。将粪便样本用PBS(100U/mL青霉素,100g/mL链霉素)1:5稀释。3000r/min离心10min,得到上清液经0.22μm滤膜过滤除菌后得到病料处理液。
将上述病料处理液接种于6孔培养板上生长旺盛的单层Vero细胞,每孔接种0.5mL,同时设立阴性对照孔,37℃含5%CO2培养箱内感作1h,弃去感作液,加入2mL维持液(1%胎牛血清的DMEM),于37℃含5%CO2培养箱内培养,每隔12h观察细胞病变,培养96h后收毒,细胞毒反复冻融3次之后再次接种Vero细胞,如此传代,直至出现典型的细胞病变。
病料处理液接种Vero单层细胞后,前两代未出现细胞病变,病毒盲传至第4代,腹泻粪便样本BKV/Yak/DF77/2021/CHN开始出现局部细胞病变,收获细胞培养物,再次接种Vero细胞48h后产生典型的细胞病变现象,主要表现为感染细胞发生颗粒性变形,细胞聚集成堆,细胞圆缩等(见图1),完全病变后则表现为大部分细胞脱落,其他未出现细胞病变,对照组细胞生长良好。
1.2牦牛AiV D病毒的RT-PCR鉴定
1.2.1病毒PCR检测
将表1中的AiV D检测引物,并送至上海生工生物技术有限公司合成,引物序列如下:
表1 AiV D检测引物
取400μL上述分离毒株的Vero细胞培养物作为病毒RNA的提取样品,参照上海英俊生物科技有限公司Trizol试剂盒(RNAisoPlus)说明书提取粪便的RNA,取400μL上清液加入700μL的Trizol,室温静置10min;加入200μL氯仿,剧烈震荡15s,取上清液;加入等体积的异丙醇充分颠倒混匀,室温静置10min;4℃、12000r/min离心15min,弃上清液,加入1mL750mL/L(经DEPC处理过的灭菌水配置)乙醇;4℃、12000r/min离心5min,弃上清液,用15μL经过DEPC处理过的无菌水溶解沉淀,置-80℃冰箱备用。
利用Prime Script TMRT试剂盒将RNA反转录成cDNA。以cDNA为模板,所述RT-PCR扩增的反应体系如下:模板cDNA 2μL,Quick Taq HS DyeMix 10μL,上游引物和下游引物各1.0μL,余下的由ddH2O补足,总量为20μL。
反应程序如下:94℃预变性2min;94℃变性30s,52℃退火30s,68℃延伸1min,共35个循环;72℃延伸8min。
扩增产物经琼脂糖凝胶电泳进行检测,结果显示分离株得到一条大小约为568bp的特异性条带(见图2),并将PCR产物送至上海生工生物技术有限公司进行测序分析,其核苷酸序列如SEQ ID NO.1所示,测定结果与NCBI已发表的AiV D序列进行基因进化树分型分析,结果显示分离株BKV/Yak/DF77/2021/CHN属于AiV D2亚型。
1.2.2纯净性检测
取400μL Vero细胞病毒液作为RNA提取样品,参照上海英俊生物科技有限公司Trizol试剂盒(RNAisoPlus)说明书提取粪便的RNA,并利用Prime Script TMRT试剂盒将RNA反转录成cDNA。以合成的cDNA为模板,应用RT-PCR检测方法,对牛轮状病毒(BRV)、牛冠状病毒(BcoV)、牛肠道病毒(BEV)进行外源病毒检测。
表2外源病毒检测引物序列
所述RT-PCR扩增的反应体系如下:模板cDNA 2μL,Quick Taq HS DyeMix 10μL,上游引物和下游引物各1μL,余下的由ddH2O补足,总量为20μL。反应程序如下:94℃预变性2min;94℃变性30s,52℃退火30s,68℃延伸1min,共35个循环;72℃延伸8min。经RT-PCR检测,AiV D分离株经外源病毒检测BEV、BcoV、BRV均为阴性。
1.3病毒蚀斑纯化
将病毒液做10倍系列稀释到10-6,将其接种到生长良好的单层Vero细胞6孔培养板中,每孔接种100μL病毒稀释液,每个稀释度接种2孔,同时设立空白对照孔,置细胞培养箱中吸附1h,每隔20min摇晃一次使病毒均匀分布。吸附后弃去6孔板中的病毒液,然后每孔加入含4%FBS的2%甲基纤维素培养基2mL,使其平铺在细胞表面,室温凝固后置于37℃含5%CO2的细胞培养箱中继续培养。待适当稀释度度出现单个蚀斑后,用无菌枪头挑选典型的蚀斑重复性克隆,接种单层Vero细胞继续培养增殖,按照上述步骤重复3次。纯化3次之后大批量扩繁病毒液作为种毒。
1.4病毒滴度的测定
将生长状态良好的Vero细胞悬浮液铺满96孔板,然后对细胞病毒培养液做连续10倍系列稀释后,加入96孔细胞板内,每一个稀释度8个孔,每孔100μL,置于37℃含5%CO细胞培养箱内感作1h,弃去病毒液,每孔加入含1%的胎牛血清DMEM培养液,37℃含5%CO2细胞培养箱培养,2~3日观察细胞的病变情况,按照Reed-Muench计算法对分离株进行TCID50测定,结果为BKV/Yak/DF77/2021/CHN=10-7.57/0.1mL。
保藏信息:
关于牦牛Aichivirus D病毒分离株的保藏编号为CCTCC NO:V202228,该病毒的分类命名为:牦牛Aichivirus D病毒BKV/Yak/DF77/2021/CHN,拉丁文学名为Yak AichivirusD,是于2022年4月10日保藏于中国典型培养物保藏中心地址为:湖北省武汉市武昌区八一路299号武汉大学校内(武汉大学第一附小对面)。
实施例2 AiV D灭活疫苗的研制
2.1病毒的繁殖
取生长状态良好的vero单层细胞,用Hanks清洗2遍,将上述免疫原性良好的疫苗候选毒株DF77细胞培养液接种到vero细胞,加入含1%胎牛血清的DMEM细胞维持液,置于37℃含5%CO2的培养箱内培养,待细胞病变为80%左右时,收获病毒培养液,反复冻融3次,4℃高速离心,获得病毒上清液作为疫苗用病毒。
2.2病毒灭活疫苗的制备
将上述免疫原性良好的疫苗候选株DF77细胞培养上清液,利用终浓度为0.5%的β-丙内酯对AiV D病毒液进行充分混匀,在37℃摇床内,灭活处理6h。取两份灭活之后的病毒液分别接种到vero细胞进行灭活检验并经vero细胞盲传两代,每代培养48~72h,观察细胞病变情况,同时设立阳性病毒对照和空白对照。
接种灭活病毒液的检测组和阴性对照组细胞无CPE,而阳性对照组出现典型的AiVD细胞病变,对检测组进行2代盲传,仍未见CPE,表明所检测灭活病毒液灭活完全。
最后将灭活的AiV D与201佐剂等体积混合,搅拌后充分混匀,在乳化机内乳化5min,制成水包油包水的灭活疫苗,分装于透明玻璃瓶内,观察疫苗为乳白色均匀混悬液,用注射器吸一滴灭活疫苗于盛水的烧杯中,疫苗均匀的分散在整个烧杯内,并将灭活疫苗在3000r/min离心5min,未见分层现象,疫苗检验合格,可用于后续实验。
表3
选取3~6月龄AiV D抗原、抗体阴性健康犊牛6头。随机分为实验组5头,对照组1头,每日观察有无临床异常,所有动物采血,用于病毒抗体水平检测。首次免疫通过颈部肌肉接种灭活疫苗(DF77);空白对照组接种相同剂量不含病毒的细胞液。疫苗接种后21日进行二免,接种方式和剂量同前所述。安全性试验结果表明,本发明DF77病毒株对犊牛安全,无副作用。疫苗接种后不同时间采血,利用抗体中和试验测定犊牛免疫后的中和抗体水平(图4)。免疫试验结果表明,DF77毒株在免疫7天后就可诱导产生高水平的抗体,SNT效价达到1400U/ml,可以作为疫苗研制的候选毒株。
上述说明示出并描述了发明的若干优选实施例,但如前所述,应当理解发明并非局限于本文所披露的形式,不应看作是对其他实施例的排除,而可用于各种其他组合、修改和环境,并能够在本文所述发明构想范围内,通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离发明的精神和范围,则都应在发明所附权利要求的保护范围内。
序列表
<110> 西南民族大学
<120> 一种牛Aichivirus D病毒分离株及其应用
<130> 6.6
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8279
<212> DNA
<213> 人工合成(1)
<400> 1
tctcctccca caaccctttt cgacggcgcg cctcggcaag gccgccgata cgcgattgtg 60
ctacctcggt accactttcg cggaataata atatgcccgg tgtagatttg cctgtttctc 120
gcaccgtacc gctcagtcgg gaatcagaaa ccggcacccc ctttcacccc acccttttcc 180
ctctccctca taacttacaa cgccttacac agaggcggcc accaaggatt agcctggtgg 240
ttataaaagg aactcgggtc tttccctctc taagccataa ggtgagttcc ctgtgtccct 300
gaatgctcgg tgaggaatgc tgcgtcgtag cgtttcgtga agtgttccaa ggttctggcc 360
tgacaagcct acagagtacc gtgatccgct gcggatgtca tcctggtaac aggaccccca 420
gtgtgcgcaa cggtatgttc ggacttcggt tcgttcaccc tggttcatgg atcgtctcgt 480
gaaagcgcgt gcgccatatc cctgtacttc aggtgcctct ttctggaccc taggaatgct 540
gcgaaggtac cccgtttcgg cgggatctga tcgcaggcta attgtctacg ggttcagttt 600
ccttttttct ttcttccaca attgactgct tgactgattc tagtgtttgc tgttctcttg 660
ctctctctgc tctcacaacg gatttctcaa ccagctcttc tctcacgacc gacaccattt 720
acacacctac tttctttgac tcttctgact cttggctcac tgacacaatg ccttcctaca 780
gcacttgtct cacttcctct gagtctcgct ggctcgagga gaggcccttc cacttccctc 840
tccccaagcc ttcttccctc tattcctgca ccgattgcgt ttccatcttt ggggatgctc 900
tcgatgctcc ctctttccca tcaccctgcc tttcacaccg gcccgccccc aagcggaccg 960
ctcccctccc tgaagacatc ctcttcgatt ctaattggcc tgaggatgtt cttcctccca 1020
actgggagaa cccaacctat taccctgact ggatccagcg tgagtttgac cgcatctgcg 1080
cgaaatctct ccctggcccc tatcaggtgc ccctcactcg ggctgagaag atctttcttc 1140
aactgctcga ccaaggggtt cacccaaatt acatcatccc cccatccaaa agctctggtg 1200
atgtggtgcg ccaaggccag tcccaaacca acatctatgg gaatggtaac aacgtcacta 1260
ctgatctagg tgctaatggt tggtccccca ccgtcaacac cggtctcggg gatggcccag 1320
tcacctcgtc tcaggatgag gtccctggcc aacccggagg ctcctccacc tccaaaaagc 1380
aaacccctgc tgcatccggc ggttcctcca ccgtcaaggt gcataactac caaaaatggt 1440
gggagcccat tgcccaaaag gcactctctc gtggtgtcga ccatgccctc gatggtatcg 1500
agggcgctgg acggctcgcg aaagacgcca tcaaatccaa gatccacagc aatggctccc 1560
aggacaccag gctattggcc ctgcctggtt ccgctctcac ccagcccgct cccaacacta 1620
cccaatctgg aaactttgct atccaatctt cttccggtta tcctactgtc actgcctacc 1680
ctcccactcc ctgcgtccca cttcctaacc ctgatcttcc atcttaccct ggccctgccg 1740
gtgaccgcac ttggttactg gacactttca cctgggacac ttcctacggg gctcgctctt 1800
ttctcggtgg ttccaattcc atgaattgga acgccctgaa tggcggtctc accttccctt 1860
tctctgacac tgacaactgg aacacgacgg gcgagtctag tcaaggcgcc gggtaccccc 1920
tgcccgctgc cttcgtcaag gcttaccctg attccgcctg ggctgccatg tacgatacca 1980
atgcactttg gaattgtggt tggcaagtca cggttgttgt caatggctct caatttcacg 2040
gcggttctct cgccatcctt gccatccctg aaggctttga ctctaccctc accggctctc 2100
gcttctatgg tgcctatacc tatccctatg tcattctcaa cctcttctct gggaatgctg 2160
tcactcttga cctcccctac attggcccgg ctcccaatgc ttactccggt ttgcattgtc 2220
cctggaccat tgtggtttct gttctcactc ctctttctcc tcctgtctcc ggctctaact 2280
ctctcggagt ttctatctat gtcacccctg tcaactcttc cttccacggg ctccgtatgg 2340
tcgcgcgaca gcactggaag acccgcgccg tccccggctc gggcgctttc ggtagcgttg 2400
ttgctgacca agaaatcccc atctacggag tctgtccttt tgatccacct gtcgactacc 2460
ttccagggga agtcacagac tggatcgagt tctgccaccg ccctgggatc ttcaacatct 2520
acaactggac ggcggcggac gacgtcggga ctaacatcgc cacagaaacg atcgactcga 2580
tcgccctgtc ggcgctggga attccgatag cgttcgttac gtctatgttc acccagtggc 2640
gtggccctct ccacctttcc ctcctcttca ctggttctgc acagcagtac gggcgtctgc 2700
tcgttgccta ctctcctcca ggcactgctg cccccaccac actccaggag gcgtcccgcg 2760
gtaccaccac catctgggac atcaacggcg tctccactct ggactttacc atccctttta 2820
tctcccccac ctattggaag gtcaacaact tggccactcc aaactccctc ctctgcaatc 2880
tcggcactat ctctgtcttt gtttctcagc agctcactgg cccccccaat gctcctgctt 2940
ctgcttctgt tgttgccttc ctctctgctt ccgatggatt caacctccgc ggaatttcca 3000
tgccctcctt ggcactccag ccacaggcgg gtgaggatct ttccgctgag acctccacct 3060
catccatcga acagggggct cctgtctccg agcccgaaac tcgaaccacc ttcgagtata 3120
aggacgctcc ccgccctcca gacaccaggc tcaacaactt cttttctttc tatcgcccca 3180
tcttcatgga gggggacaat tactccactc agctcaccac cggaatcgtg atgatggaac 3240
tcaaccccgt cacatggatc agaaacgctg gtacgggtga cactcttcct cttcttcttt 3300
cctgcttcac atacatccgc ggtgaccccc gcgtcgccat ccgggtgtca aaccccgctg 3360
ctttcactgc ttatctctcc ttcttcttca tccctcctgg tggctcgaca ccgaatacca 3420
atttcaccaa tatccagttg gcggattgtt ataacgtgcg ggcccccatc ccccctacca 3480
gcgaggacac catctgcctc tctattccct acgcgaaccc tctgtccgcc atccccactt 3540
ccttcatggg attcgccgac ttctcgggcg gaacagacgt gatcaacacc acgtttggta 3600
cgctcgtgat aacgacgacg ttccaggggg atgtggagga atcccagtac cccactatct 3660
acccctccat cgcgtttggg aatttcagag cgtggatccc tcgcgcccct cccaccactg 3720
cttctgctcc ctctaccacc tctgctgctt ttgctgatcc ccgtgggact gcgctggagt 3780
actacaagct ccatgcgaag gctcaccccc aacttcccat tgccctcgcc cgtcgccagt 3840
gccaagacac tgaggtgccg tctctgctca acccagactc gcgcatctac attgtcaagg 3900
cgcagcgccc cacctatgtt cattgggcta tccgtgcggt ccatcccgat ggatcctcgg 3960
aacaaatttc cctctcccgt tccggcattg gctgcgtgat cgcctacgag gaatgtgaag 4020
gtgaactcta ccaggaggtc gctcctggtt gctgggtcac cgccacttgc ctcgttggcg 4080
agccgtggga atacaatgct gagaacaact gcaccacctt tgtctccaat gtgactggtg 4140
tctctctccc caacaccggt tactccctca tctttggggt tttcgctctc tctgccgtca 4200
gcctggtggc cgcgcaagcg ctctcaggcc gccacgccca acgtcaggga gactctgatt 4260
cttccgcttc ctttgcatct gctcgcccca tccccgctcc ccgttctctc acttgcacca 4320
tcttctctac ttctgagtct gacgccccta ggccgcgccc gcgtcgccaa accaggcgat 4380
gccgccggca aagtacgtcg gattctgact ctgacccctc ttggactgca actccccgtc 4440
tcatcaagga ggcgacgtct gccgcccgct acgtggcgga cacggcgaag gagctcgagc 4500
tgaaggccac atccaacaac ctgatgctct gctcctccga cctccgctgc gcggcggaca 4560
aagtttccgc ttccgttgat gggttccggg agtttctcgg ctcttggtcc tcctccttca 4620
aggataatgt cggtgatgcc gtctccagcg gtattgccac cttcctgaag tgggtcgcca 4680
agtgttttgg ctatctctta gtcatttttg gttcccctac ccccatgtct ctcactggtg 4740
ttattcttct cctctgtgct gatctctctc ccgacattgc tgggttcttc accaaagttc 4800
ccaacgctgt tggcgctctt tacttttgga ttgccaacaa attaggcctc tcagtctcag 4860
cccaggagtg cgctgaacag ggtgtccaac atcagagcgg tcttggcgac ttcaacacct 4920
tcgccaacgc cgtgaagaac atggaatacc ttgccagtaa atcctgggaa tggactgcca 4980
aattacttga ttggattcag ggcaaagtca aaactgaccc aaacctccaa ttggccaatg 5040
ctcacgacga gatcctccga ttttatcgtg agtccattga agcgctatcc gcagttccca 5100
acgctgcggc ggccgctgat tcaatttcca ggctgcaaga attggcaaaa attgcagccg 5160
atgccaaatc tggccctcac tcaacataca ttcagcaatc catcaaaaat ttcaccaccg 5220
tcctcaccaa ggctgggaag cgctactcag gtaaccgccc cgaacccttc gtggtgtacc 5280
tgactggcgc ccctggctgc ggtaaatccc tccttgcttc catccttgcc gcaacactcg 5340
cgaaacgcct cggtggtagc gtcgacgacg tctacgcccc cgccgccgcc gactgcgagt 5400
tctatgacgg gtatactggc cagtccgtcc acttcatcga cgacattggc caggaccctg 5460
aaggcaagga ctggaagaat ttccccaatc tcgtctgctc tgctcccttc atcctcccca 5520
tggccgcgat cgaagacaag ggcacttatt acacatccag ggtaataatc gccacctcaa 5580
actttgatcg cgcgaacgac cgcgctgccc gttgcatgcc cgccctggaa cgcagactcc 5640
acctgcgtat acagatcggt gcacggggtg accggaagtt caacgccgaa gatgccctca 5700
gagacacctc cctccctaac caatctaaat acctcaccca ccactgtaaa ttctctgatc 5760
tttcctgcta caccatgacc gtcgagcgca actccatcta cagacctgac tctggcaggt 5820
ttgacacgtt cgacgagctc gtggtcattt ttcgccgcgt tgagaacaac gctggcacct 5880
ctgaaatggt gaggaacatc gtgagacaag gagatagggt gattactcga aaccccgagc 5940
acgcacctta tcacaccgtc atccacgact tgctcaccag ctctcatgtc cccgtgcctg 6000
tcgaccttgg ccgcgccata gagacaaacc agcctctatc ggtgtgtgac aagatctggc 6060
agtaccggaa acccatcttt gccaccacta ctttcatttc tgtctgttct ttccttgcaa 6120
ctctcctcta ccttgcctac cgcctgtgga aatctcgcca cgaagaggag ggcaaagagc 6180
aggctgctta ttccggtcta ccacacctct accggaaggg caagcaggct cgcccgactc 6240
ccaagccccg ctccacccag gggcccgtgg tgaggcaggg cggcgtcaca cccgccatgc 6300
ctaacatcca caggaatgtt cttcctgtcg ctgggatatg ggagaaggag tccaaccact 6360
cctccgcctt tgtccttttc tcccgctatg ttcttatccc cactcacatc gttgctggag 6420
ctccttacat caagctcggc aacgatctct ttgacactgc tactctccct gagcctcttg 6480
atcttggtcc tgaacttcaa ctctggttct tccccactct ccgccagtac aaggacatgc 6540
gccgcttcat tgggatgcat cctcacaaga ctggctgcct tctttctgca cacgggaaca 6600
actacacgta cgtccggttc tcgaattgcc ggcgtggtcc tctcgccatt ggcgggcagc 6660
acgtcatgga cggtgcctac gtttacaacg cggcaacgtt cggtggcctc tgcggctctc 6720
ccttggtcac ggatgacccc gccgggactt cgattctcgg aattcacgtg gcaggcattc 6780
ccggatgcac tggcttttct gtccctctcc atcctttcac ggagcaaatc gccgactatg 6840
caacccagca tcagtctctg atcttctcca acggctctct caaagacgag gggctccccg 6900
gtgtcaacat caacaggaag acgcgcctga gaccaagccc ggcctacggt gcgttccctg 6960
tgaagaagga accggctgct cttcgtcgtt ctgacccccg ccttgaggag ggcatcgatc 7020
tggacactca actcttcgcc aaacacaaca aaggcgacca aattgatgaa tggccctgcc 7080
ttaaggaagc tattgctctc tacacttcca ctctccctga tcacttccgg atcctcacac 7140
aagaagaggc tatccatgga actccctcca tggaaggcct cgacatgaat caggccgctg 7200
gatacccctg gaacaccttg ggaaggtcac gtcgctctct ctttgacgaa ccgaccccgg 7260
gtatctatgt accaaaacct gaacttcagg cggcaattga ccgctgtctg gagaaccctg 7320
agtacatcta ctccaccttc ctgaaagatg aactcaggcc attggataaa gtgaagaagg 7380
gcctgacccg tgccgttgag tgcgctccca tccatgccgt cattgctggc cggatgctcc 7440
ttggtggtat catcgaacac taccagggac gccccggcga gtatggcagc gcggttggct 7500
gcaaccccga ctaccactgg actcccttct tctacaaatt tgccaaatat gaaaatgtgt 7560
gggatcttga ctacaaatgc tttgatgcta ctatcccttc tgttcttctc tctgcttatg 7620
ctgattgggt gcacaaggtg acgggcgatc tgcgtgcacg ccagtacgta gaatccatcc 7680
gttggtccaa acatgtgtac gggagtgagt tatatgagat gattggcggc aatccatccg 7740
gatgtgtcgg cacatcgata atgaactcct ggtgcaacaa tgttgcggtc ctctccgcct 7800
tgatgcactg ctctggctct gatttcaacc ctcgtgatta tgaaattctt tgctatggcg 7860
atgatgtgtt gtacgcgtgt gagcccaatg tccaccctcg cgacattaag gctttctacg 7920
acaaatacac cacactcatt gtcacccctg cctctaagac ttctgacttt cctgattctt 7980
ccaccatcta tgacgtcacg tttctgaagc gctggttcgt cccggatgat atcaggggga 8040
tctacatcca ccctgtcatg actccggata cgtacgagca atcagtcatg tggatgaaag 8100
atggtgattt ccagtgtatc gttgactctc tgtcttatct ggctttccac tccggaccca 8160
aaacctacaa ggcttggtgt cagaaggtgg gagatcaggc ccggctccac ggagtcgacg 8220
tccatttcct gccctatgaa ttcctccagg ctaagtgggt taacttggtt tcggcgtga 8279
<210> 2
<211> 20
<212> DNA
<213> 人工合成(2)
<400> 2
ccaccaggta tgaattggac 20
<210> 3
<211> 20
<212> DNA
<213> 人工合成(3)
<400> 3
cgccatctga gtgattactc 20
<210> 4
<211> 18
<212> DNA
<213> 人工合成(4)
<400> 4
cgagttgaac acccagat 18
<210> 5
<211> 18
<212> DNA
<213> 人工合成(5)
<400> 5
gagacgggca tctacact 18
<210> 6
<211> 19
<212> DNA
<213> 人工合成(6)
<400> 6
agcaacactg gattgtgcc 19
<210> 7
<211> 18
<212> DNA
<213> 人工合成(7)
<400> 7
ggagtagtcc gactccgc 18
Claims (10)
1.一种牛Aichivirus D病毒分离株,其特征在于,该分离株的微生物保藏编号为CCTCCNO:V202228。
2.权利要求1所述的牛Aichivirus D病毒分离株在制备用于预防和/或治疗牛Aichivirus D病毒所致疾病产品中的应用。
3.根据权利要求2所述的应用,其特征在于,所述产品为疫苗或药物。
4.根据权利要求3所述的应用,其特征在于,所述疫苗选自灭活疫苗、弱毒疫苗、减毒活疫苗、基因工程疫苗、多肽疫苗中的一种或几种。
5.利用权利要求1所述的牛Aichivirus D病毒分离株制备的抗牛Aichivirus D病毒抗体。
6.含有权利要求5所述的抗牛Aichivirus D病毒抗体的药物。
7.权利要求1所述的牛Aichivirus D病毒分离株或权利要求5所述的抗牛AichivirusD病毒抗体在制备牛Aichivirus D病毒所致疾病的检测试剂中的应用。
8.一种疫苗组合物,其特征在于,包括有效量的权利要求1所述的牛Aichivirus D病毒分离株。
9.根据权利要求8所述的疫苗组合物,其特征在于,所述疫苗组合物还包括药物或兽医学接受的载剂。
10.权利要求8或9所述疫苗组合物的制备方法,其特征在于,培养增殖牛Aichivirus D病毒分离株,灭活后制备成疫苗产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210630701.8A CN114958780B (zh) | 2022-06-06 | 2022-06-06 | 一种牛Aichivirus D病毒分离株及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210630701.8A CN114958780B (zh) | 2022-06-06 | 2022-06-06 | 一种牛Aichivirus D病毒分离株及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114958780A CN114958780A (zh) | 2022-08-30 |
CN114958780B true CN114958780B (zh) | 2023-04-25 |
Family
ID=82959989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210630701.8A Active CN114958780B (zh) | 2022-06-06 | 2022-06-06 | 一种牛Aichivirus D病毒分离株及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114958780B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113474456A (zh) * | 2018-11-14 | 2021-10-01 | 博德研究所 | 基于crispr系统的液滴诊断系统和方法 |
CN114561366A (zh) * | 2022-03-30 | 2022-05-31 | 西南民族大学 | 一种山羊库布病毒分离株及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2597921A1 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
CA2646623A1 (en) * | 2005-12-14 | 2007-08-23 | The Board Of Regents Of The University Of Oklahoma | Rna virus vaccines and methods |
-
2022
- 2022-06-06 CN CN202210630701.8A patent/CN114958780B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113474456A (zh) * | 2018-11-14 | 2021-10-01 | 博德研究所 | 基于crispr系统的液滴诊断系统和方法 |
CN114561366A (zh) * | 2022-03-30 | 2022-05-31 | 西南民族大学 | 一种山羊库布病毒分离株及其应用 |
Non-Patent Citations (10)
Title |
---|
Chang JT等.Prevalence and genetic diversity of bovine kobuvirus in China.《ARCHIVES OF VIROLOGY》.2014,第159卷1505-1510. * |
Hao LL等.Bovine kobuvirus-A comprehensive review.《TRANSBOUNDARY AND EMERGING DISEASES》.2021,第68卷1886-1894. * |
Jeoung, HY等.Three clusters of bovine kobuvirus isolated in Korea, 2008-2010.《Virus Genes》.2011,第42卷402-406. * |
Yan N等.Aichivirus D isolate BKV/Yak/SCDF77/2021/CHN, complete genome.《NCBI GenBank database》.2023,OP776109. * |
易春华 ; 谢齐斌 ; 唐薇薇 ; 朱春刚 ; 秦长串 ; 伍和明 ; 韦达有 ; .猪嵴病毒VP1基因序列测定与分析.南方农业学报.2016,(第04期),全文. * |
曹恭貌 ; 张斌 ; 岳华 ; 费磊 ; 任玉鹏 ; .四川部分猪场PEDV、TGEV、GARV和PKV感染状况调查.动物医学进展.2016,(第01期),全文. * |
李慧平 ; 汤承 ; 岳华 ; .实时荧光定量RT-PCR检测牛库布病毒.畜牧兽医学报.2020,(第04期),全文. * |
杨德全 ; 葛菲菲 ; 鞠厚斌 ; 刘健 ; 王建 ; 周锦萍 ; .嵴病毒(Kobuvirus)研究进展.中国预防兽医学报.2012,(第12期),全文. * |
白小磊 ; 崔进 ; 崔甜甜 ; 陈耀 ; 石庆伟 ; 冯嘉萍 ; 王林川 ; 张桂红 ; .广东部分地区猪流行性腹泻病毒流行病学调查.中国兽医学报.2016,(第11期),全文. * |
耿金静等.牛病毒性腹泻病原的分子生物学与检测技术研究进展.《西北民族大学学报(自然科学版)》.2020,全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN114958780A (zh) | 2022-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111632137B (zh) | 猫杯状病毒病、猫传染性鼻气管炎和猫泛白细胞减少症三联疫苗及其制备方法和应用 | |
CN104877972B (zh) | 一种重组猪伪狂犬病毒gE/gI双基因缺失株及其应用 | |
CN108913666B (zh) | 一种导致鸭脾脏坏死的鸭呼肠孤病毒及其灭活疫苗和应用 | |
CN103725651B (zh) | 一株猪流行性腹泻病毒及其应用 | |
CN113198011B (zh) | 一种鸭腺病毒3型菌株灭活疫苗及其应用 | |
CN113493775B (zh) | 一种猪德尔塔冠状病毒毒株及其应用 | |
CN108486067A (zh) | 猪流行性腹泻病毒变异株及其制备的灭活疫苗和应用 | |
CN101948811A (zh) | 用反向遗传操作拓展口蹄疫疫苗株抗原谱及疫苗制备方法 | |
CN111073863A (zh) | 猪流行性腹泻、猪德尔塔冠状病毒二联弱毒疫苗及其制备方法 | |
CN104928260B (zh) | 一种牛传染性鼻气管炎病毒ibrv-jn03分离株及其应用 | |
CN114561366B (zh) | 一种山羊库布病毒分离株及其应用 | |
Li et al. | Evaluation of immunogenicity and protective efficacy of a novel Senecavirus A strain-based inactivated vaccine in mice | |
Niu et al. | Characterization and pathogenicity of the porcine epidemic diarrhea virus isolated in China | |
CN108660118A (zh) | 一种导致鸭关节炎的新型鸭呼肠孤病毒及其应用 | |
CN116426487A (zh) | 一种猪流行性腹泻病毒株及其在疫苗制备中的应用 | |
CN112063596A (zh) | 鸽副黏病毒1型ppmv-1/bj-c株及其应用 | |
CN115161291A (zh) | 一株猫细小病毒毒株及其应用 | |
CN103865884A (zh) | 鸭病毒性肝炎二价蛋黄抗体及其制备方法和应用 | |
CN102952785B (zh) | 猪伪狂犬病毒、疫苗组合物及其应用 | |
CN104130981A (zh) | 鸡传染性支气管炎病毒疫苗株及其在制备灭活疫苗中的应用 | |
CN114958780B (zh) | 一种牛Aichivirus D病毒分离株及其应用 | |
CN108498794B (zh) | 一种防治新型鸭呼肠孤病毒的灭活疫苗及其制备方法 | |
CN114921422B (zh) | 一种犬源猫细小病毒分离株及其应用 | |
CN1242065C (zh) | 猪繁殖与呼吸综合征重组腺病毒和疫苗 | |
CN117106731A (zh) | 柯萨奇病毒a6型cva6-km-j33及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |